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repairs of popliteal artery aneurysms
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Objective: Endovascular repair has emerged as a treatment option for popliteal artery aneurysms. Our goal was to analyze
outcomes of elective and emergency endovascular popliteal artery aneurysm repair (EVPAR).
Methods: This was a retrospective review of clinical data of patients treated with EVPAR at our institution between 2004
and 2010. Stent-related complications, patency, outcome limb salvage, and survival were evaluated and analyzed.
Results: EVPAR was performed in 31 limbs of 25 patients (mean age, 81 years; range, 65-89 years). Repair was elective in
19 limbs (61%) and emergent in 12 (39%). One aneurysm ruptured and 11 presented with acute thrombosis. All 11
underwent thrombolysis before EVPAR. Patients were implanted with a mean of 2.1 Viabahn stent grafts (range, 1-4).
Ten procedures (32%) were performed percutaneously and 21 by femoral cutdown. Technical success was 97%. Overall
30-day mortality was 6.4%, with 0% in the elective group, and 16.7% in the emergent group (P [ .14). Early compli-
cations included graft thrombosis in two limbs (6.4%) and hematoma in four (13%), all after percutaneous repair.
Myocardial infarction and thrombolysis-associated intracranial hemorrhage occurred in one patient each (3.2%). The 30-
day primary and secondary patencies were 93.6% and 96.7%, respectively, and were 100% in the elective group and 83.3%
and 91.6%, respectively, for the emergent group. Mean follow-up was 21.3 months (range, 1-75 months). Primary
patency at 1 year was 86% (95% for elective, 69% for emergent; P [ .56), secondary patency at the same time was 91%
(elective, 100%; emergent, 91%). One-year limb salvage was 97%. Two-year survival was 91% for the elective group and
73% for the emergent group (P [ .15). Five stent occlusions were encountered after 30 days, four in the elective group.
Four underwent successful reintervention, two had bypass, and two had thrombolysis, followed by angioplasty. The ﬁfth
patient was asymptomatic and nonambulatory and remains under observation. Stent graft infolding occurred in one limb
(3.2%), with no clinical sequelae. No stent migration or separation was observed. One stent fracture was noted in an
asymptomatic patient. Three (10%) type II endoleaks were detected but none had aneurysm expansion. One (3.2%) type I
endoleak was treated percutaneously with placement of an additional stent graft. Overall, major adverse events, including
death, graft occlusion with or without reoperation, or reoperation for endoleak or stent infolding occurred after 11
procedures (35.5%). On univariate analysis, no factors predicted stent failure, including runoff, antiplatelet therapy,
emergency repair, number of stents implanted, heparin bonding of the stent, or degree of stent oversizing.
Conclusions: These results support elective EVPAR in anatomically suitable patients with increased risk for open repair;
however, major adverse events after EVPAR, mainly after emergency repairs, are frequent. A prospective randomized
multicenter study to justify EVPAR in the emergent setting is warranted. (J Vasc Surg 2013;57:1299-305.)Popliteal artery aneurysms (PAAs) are themost common
peripheral arterial aneurysms, accounting for approximately
70% of all peripheral arterial aneurysms.1 Approximately
50% of the patients with PAAs present with a variety of
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://dx.doi.org/10.1016/j.jvs.2012.10.112and tissue loss; swelling, venous thrombosis, or numbness
due to compression in the popliteal space; and painful blue
toes or symptoms of acute limb ischemia. Limb loss with
acute presentation is not infrequent, and the amputation
rate after acute thromboembolism can be as high as 30%.2,3
Rupture is the most frequent complication of aortic,
iliac, and femoral artery aneurysms, but PAA rupture is
rare. To avoid complications, repair of asymptomatic
PAAs has been recommended when the aneurysm diameter
is $20 mm or when mural thrombus is present within the
aneurysm. Symptomatic aneurysms should be repaired
whenever possible.4
Open surgical repair with endoaneurysmorrhaphy and
saphenous vein bypass is accepted as the gold standard
for surgical treatment.5 However, as with aortic and iliac
aneurysms, endovascular therapy has emerged as a less-
invasive alternative strategy for repair of PAAs. The ﬁrst
report of endovascular repair of a PAA (EVPAR) was
published in 1994.6 Since then, there has been great
enthusiasm for this minimally invasive approach. The adv-
antages of endovascular repair are its minimally invasive1299
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stay.7 However, the long-term durability of endovascular
therapy is still unknown, and results are inconsistent among
the few reported series. A potential problem with endovas-
cular repair is that the stent graft crosses the knee joint,
which may result in kinks, fractures, and thrombotic occlu-
sion. This is of particular concern in younger, active indi-
viduals because of the increased forces on the stent with
ﬂexion and extension of the leg at the knee joint.8
We reported results of surgical treatment of PAAs
previously.4,5 EVPAR was ﬁrst performed at our institution
in 2004, and indications have evolved as experience with
stent grafts increased. First, it has been reserved for elderly
patients and for those considered to be at high risk for elec-
tive open surgery. In these patients, we have adopted
a strategy of EVPAR if anatomically feasible. We have
subsequently extended the “endovascular-ﬁrst” approach
to similar patients with acute limb ischemia due to throm-
boembolic complications of their PAAs and, in one patient,
with an aneurysm rupture. We continued to perform open
repair in good-risk patients and in those aged <70 years.
During the period reported in this study, 87 patients
underwent 113 PAA repairs. The endovascular cohort re-
ported represented 29% of our patients and 27% of the
PAA repair procedures. The aim of this study was to
analyze the early and midterm results of EVPAR performed
in both elective and emergency settings.
METHODS
Study design, patients, and data collection. The
clinical data of all consecutive patients who underwent
EVPAR at Mayo Clinic, Rochester, Minnesota, between
March 1, 2004, and January 31, 2010, were reviewed
and analyzed. The Mayo Foundation Institutional Review
Board approved the study. Hospital records, clinic notes,
and operative reports were used to compile a database of
all PAA repairs. Patients were grouped by the timing of
the repair (elective vs emergent) and were then compared,
with graft patency as the primary end point. Secondary end
points included complication rates, frequency of endoleak,
limb salvage, and survival.
Data analysis and statistical methods. Statistical
analysis was performed using Stata software (Stata Corp,
College Station, Tex). The Kaplan-Meier life-table method
was used to calculate primary and secondary patency curves.
Differences in patency rates were evaluated by the log-rank
test. The Fisher exact test was used to evaluate differences
in categoric variables between patient groups. The predictive
value of the different variables on stent failure was assessed
in univariate analysis. A P value of <.05 was considered
statistically signiﬁcant.
Deﬁnitions. PAA was deﬁned as focal dilation of the
popliteal artery by >50% over the expected normal diam-
eter (0.9 6 0.2 cm), as measured with ultrasound
imaging.9 Successful stent graft deployment was con-
ﬁrmed by completion angiography and, selectively, by
intravascular ultrasound imaging. Procedural success was
deﬁned as complete exclusion of the aneurysm immediatelyafter balloon dilatation of the stent graft, with preservation
of the distal runoff. Endoleak was deﬁned as radiographic
evidence of blood ﬂow outside the stent graft. Patency was
deﬁned clinically as continued presence of palpable pulses
or by duplex ultrasound imaging showing <50% stenosis of
the luminal diameter of the stent graft. Limb salvage was
deﬁned as preservation of enough of the foot to allow
unassisted ambulation.
Endovascular technique. All procedures were per-
formed under general or local anesthesia in the operating
room by vascular surgeons and, in some patients, with an
interventional radiologist. Access to the ipsilateral common
femoral artery was achieved by cutdown or percutaneous
technique based on surgeon preference. Anticoagulation
was achieved with heparin dosed based on patient weight.
An intraoperative femoral arteriogram with runoff was
performed to determine the characteristics of the aneu-
rysm, proximal and distal landing zones, and runoff vessels.
Intravascular ultrasound imaging was also used selectively
to measure the proximal and distal diameters and to assess
good deployment. In 20 cases, a preoperative computed
tomography angiogram (CTA) was performed that enabled
diameter measurement of the proximal and distal landing
zones and aided in selection of stent graft diameter. Via-
bahn stent grafts (W. L. Gore & Associates, Flagstaff,
Ariz) were used in all procedures: 12 limbs received
regular, 17 received heparin-bonded stent grafts, and one
patient received both types.
Stent graft diameter was oversized by 1 to 2 mm, and
the minimum proximal and distal landing zones length was
15 mm. Multiple stent grafts were used in cases involving
long aneurysms or diameter mismatch between the prox-
imal and distal landing zones. The distal stent was placed
ﬁrst, followed by the proximal stent, with a minimum over-
lap of 20 mm. After deployment, the stent graft was dilated
with a noncompliant balloon to ensure proper apposition.
Antiplatelet therapy was initiated on the operative
day with clopidogrel (300 mg) and acetyl salicylic acid
(325 mg). Antiplatelet therapy duration varied from
3 months to lifetime, depending on surgeon preference.
Thrombolytic therapy was initiated in patients with
acute limb ischemia and thrombosis of the aneurysm and
runoff vessels with less than Rutherford class II-a.10 The
agent of choice was alteplase (0.5 mg/h). Percutaneous
access was performed with ultrasound guidance. The type
and length of the fenestrated infusion catheter varied
according to each surgeon’s discretion. Follow-up angiog-
raphy was performed at 12- to 24-hour intervals. The
thrombolytic infusion was continued until the runoff
anatomy was deﬁned. Once the thrombus had cleared,
the endovascular repair was performed as described.
Patients with acute presentation were anticoagulated post-
operatively selectively.
Postoperative follow-up. Follow-up information was
obtained from medical records and supplemented with
phone interviews when survival and limb loss information
could not be obtained from medical records. The ﬁrst
follow-up visit was scheduled after 3 months. During the
Table I. Demographic data of 25 patients with 31
popliteal artery aneurysms (PAAs)
Variable
Mean 6 SD (range) or No. (%)
(N ¼ 25)
Age, years 81 6 5.9 (71-89)
Male 24 (96)
Bilateral PAAs 6 (24)
Hyperlipidemia 20 (80)
Hypertension 19 (76)
Abdominal aortic aneurysm 19 (76)
Chronic kidney diseasea 13 (52)
COPD 9 (36)
Current smoker 6 (24)
History of myocardial infarction 5 (20)
Diabetes mellitus 4 (16)
History of stroke 2 (8)
COPD, Chronic obstructive pulmonary disease; SD, standard deviation.
aDeﬁned as a glomerular ﬁltration rate of <60 mL/min/1.73 m2.
Table II. Indications for endovascular repair of 31
popliteal artery aneurysms (PAAs)
Variable No. (%)
Total PAAs 31 (100)
Elective 19 (61.2)
Asymptomatic 17 (54.8)
Blue toe syndrome 2 (6.5)
Emergent 12 (38.7)
Acute limb-threatening ischemia 11 (35.5)
Rupture 1 (3.2)
Table III. Early complications in 31 patients after
attempts at endovascular repair of popliteal artery
aneurysms (PAAs)
Variable
Limbs No. (%)
(N ¼ 31)
Technical success 30 (97)
30-day mortality 2 (6.4)
Elective 0/19 (0)
Emergent 2/12 (16.7)
Primary patency #30 days 29/31 (93.6)
Elective 19/19 (100)
Emergent 10/12 (83.3)a
Secondary patency #30 days 30/31 (96.7)
Elective 19/19 (100)
Emergent 11/12 (91.6)a
Groin hematoma 4 (13)
Myocardial infarction 1 (3.2)
Intracranial bleeding 1 (3.2)
aOne patient died with a patent graft.
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brachial indices (ABIs), duplex ultrasound imaging, and
computed tomography angiography (CTA). Subsequent
visits included measurement of ABI and ultrasound assess-
ment, and a CTA when abnormal ﬁndings were present in
the noninvasive tests. Patients were advised to return every
6 months thereafter. Patency rates were based on the last
imaging study or documented pulses on physical exami-
nation by a physician.
RESULTS
Patient population. During the 6-year period, 31
PAAs were treated in 25 patients with a mean age of 81
years (range, 71-89 years). Six patients (24%) had bilateral
aneurysms, including the only woman in the study.
Comorbid diseases included hyperlipidemia in 20 (80%),
hypertension in 19 (76%), chronic kidney disease in 13
(52%), diabetes mellitus in four (16%), and a prior
myocardial infarction in ﬁve (20%; Table I).
Initial presentation and timing of intervention. Of
the 31 PAAs treated during the 6-year study period, 12
limbswere classiﬁed as emergent, consisting of 11with acute
limb-threatening ischemia and one aneurysm rupture. Of 19
limbs that had elective repair, there were 17 asymptomatic
and two symptomatic limbs with blue toe syndrome. Theindications for repair in asymptomatic limbs included size
>2 cm or the presence of mural thrombus, or both
(Table II). All patients treated as emergencies presented
with acute onset of foot or leg discomfort, foot coolness, and
rest pain. No patients had a major sensory or motor deﬁcit
on physical examination, and all were classiﬁed as having
Rutherford class II-a or early II-b limb ischemia.
Intraoperative data. Viabahn stent grafts were used in
all 31 limbs. A mean of 2.1 stents (range, 1-4 stents) per
limb were implanted. Technical success was achieved in
30 limbs (96.8%).
Early (30-day) results. No deaths occurred in the
elective group, but two of the 12 patients with acute presen-
tation died, for an overall mortality of 6.4% (2 of 31; elec-
tive, 0 of 19 [0%]; emergent, 2 of 12 [16.7%]; P ¼ .14).
The ﬁrst death occurred with an unsuccessful attempt of
achieving patency of the deployed endograft. Completion
arteriogram in this patient revealed sluggish ﬂow and distal
ﬁlling defects in the popliteal artery. These ﬁndings promp-
ted conversion to open repair. Thrombectomy of the distal
popliteal artery and crural vessels was performed, followed
by a femorotibial bypass using a polytetraﬂuoroethylene
(PTFE) graft. Outﬂow could not be restored, and the
patient underwent a below-knee amputation the next day.
The patient died 2 days later of a myocardial infarction.
Another death occurred #30 days in the emergent
group. This patient underwent successful thrombolysis
and successful stent graft deployment. Thrombolysis was
performed for 24 hours, no bolus dose was given, and
the infusion rate of tissue plasminogen activator was set
at 0.5 mg/h. However, the patient became coagulopathic,
developed a groin hematoma requiring reoperation, and
sustained an intracranial hemorrhage on the evening of
the operation. He died of brain stem herniation on the ﬁrst
postoperative day.
Early complications are listed in Table III. Two graft
thromboses occurred #30 days, one in a patient described
before, who died 2 days after an open repair done for
Table IV. Early and midterm complications
Complications No. (%)
Stent thrombosisa 6 (19.2)
Thrombolysis and PTA 3 (9.6)
Bypass 1 (3.2)
Endoleak
Type I 1 (3.2)
Type II 3 (6.4)
Stent infolding 1 (3.2)
Stent fracture 1 (3.2)
Stent separation 0 (0)
PTA, Percutaneous transluminal angioplasty.
aIncludes two occlusions <30 days.
Fig 1. Primary patency of 31 stent grafts after endovascular repair
of a popliteal artery aneurysm (PAA).
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acute group; this endograft was successfully reopened with
thrombolysis and balloon angioplasty. One patient died
with a patent graft after emergency repair.
Overall primary patency #30 days in the 31 PAAs was
93.6% (29 of 31), 100% after elective and 83.3% (10 of 12)
after emergency repair. Secondary patency of the stent
grafts by 30 days was 96.7% (30 of 31). Combined
freedom from graft occlusion or death at 30 days was
75% after emergency repair and 100% after elective repair.
Of the 10 (32%) procedures performed percutaneously,
four patients developed a groin hematoma. Three of them
required reoperation and bleeding in the fourth patient
stopped after manual compression. Early major adverse
events leading to death or requiring reoperation for graft
occlusion or hematoma evacuation occurred in six of the
31 PAAs (19.4%).
Three type II endoleaks (9.6%) occurred, all in the
elective group. These were visualized on completion angio-
grams. All had resolved by 3 months as documented by
duplex ultrasound imaging.
Midterm results. Secondary interventions to treat
stent graft thrombosis, in-folding, or endoleaks were per-
formed in ﬁve limbs, for a reintervention rate after
discharge of 16% (emergent, 2 of 12 [16.6%]; elective, 3 of
19 [15.8%]). When early complications were added to late
secondary interventions, major adverse events totaled 11
limbs (35.5%).
In addition to the two patients with early thrombosis,
ﬁve patients developed stent graft occlusions after 30
days, four in the elective, and one in the emergent group.
Four of these underwent reintervention, and three were
performed percutaneously. The occlusion in the emergent
group occurred at 2 months. This patient underwent
successful thrombolysis and balloon angioplasty. One of
the four stent graft occlusions in the elective group
occurred at 2 months due to in-stent stenosis. This was
successfully treated with thrombolysis and balloon angio-
plasty, and the stent remained patent at 13 months of
follow-up. Another occlusion was encountered after 22
months. Conversion to open repair was performed, and
the patient underwent a femoral-to-tibioperoneal bypass
with great saphenous vein. The third occlusion was found
at 18 months during a follow-up visit. The patient was
asymptomatic, with an ABI of 0.7, and remains in observa-
tion. The ﬁnal patient in this group underwent total knee
arthroplasty at 11 months after stenting, and the stent
occluded after the intervention, requiring conversion to
open aneurysm repair with a bypass.
Two of the primary thrombotic complications occurred
in stent grafts without heparin bonding (2 of 12 [16.7%]),
four occurred in those with heparin bonding (4 of 17
[23.5%]; P¼ .71), and one thrombosis occurred in a patient
who had stents with and without heparin bonding.
One type I proximal endoleak (3.2%) was found on
follow-up CTA at 6 months. This was successfully treated
with placement of an additional proximal stent graft. The
aneurysm size remained stable at 6 months, and no furtherendoleak has developed. One case (3.2%) of infolding was
discovered by CTA in an asymptomatic patient. The
patient was treated percutaneously with balloon angio-
plasty of the stent graft.
One patient developed a partial stent fracture at 10
months. The stent fracture was detected on a plain X-ray
imaging done for other purposes and conﬁrmed with
CTA. He was asymptomatic at the time and remains in
observation.
Early and midterm complications are listed in Table IV.
The 2-year survival was 93% for the elective group and 73%
for the emergent group (P ¼ .15). Limb salvage was
96.8%. One patient (3.2%) underwent a minor amputation
at the metatarsal level and maintained the ability to walk
independently.
Primary patency at 1 year was 86% (elective, 95%;
emergent, 69%; P ¼ .56), and secondary patency at the
same time was of 91% (elective, 100%; emergent, 91%;
Figs 1-4). Univariate analysis of factors, including runoff
vessels, antiplatelet therapy, emergency repair, number of
stents, heparin bonding, and degree of stent oversizing,
failed to reveal predictors of stent graft failure.
DISCUSSION
The most common complications of PAAs are throm-
bosis and embolization resulting in distal limb ischemia.
Fig 2. Secondary patency of 31 stent grafts after endovascular
repair of a popliteal artery aneurysm (PAA).
Fig 3. Primary patency after elective and emergent endovascular
repairs of a popliteal artery aneurysm (PAA).
Fig 4. Secondary patency after elective and emergent endo-
vascular repairs of a popliteal artery aneurysm (PAA).
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present with pain and swelling in the popliteal fossa and
symptoms of lower extremity ischemia.11,12
Duplex ultrasound imaging is the most useful screen-
ing test and easily differentiates a PAA from other
common pathologies such as a Baker cyst or tumors. A
CTA, magnetic resonance angiogram, or conventional
contrast arteriogram is required to plan open or endovas-
cular repair. Early diagnosis of asymptomatic PAA is help-
ful to avoid emergency repair and provide the best chance
for long-term bypass or stent graft patency and limb
salvage.13
Indications for PAA repair include (1) size >2 cm in
diameter, particularly if signiﬁcant mural thrombus is
present; (2) local compression or lower extremity ischemia
symptoms (claudication, rest pain, or tissue loss); (3) rapid
growth; (4) acute thrombosis or distal embolization; and
(5) rupture.6,14 Some authors have suggested aggressive
repair of PAAs with a diameter of <2 cm if thrombus is
present15 because the amputation rate for acute thrombosis
of a PAA is as high as 30%.Open repair with saphenous vein grafts provides excel-
lent limb salvage, with a 5-year primary rate of 85% and
secondary patency rate of 94%.5 Open repair through the
posterior approach, using a PTFE graft, can also provide
excellent results.16 The ﬁrst endovascular repair of a PAA
was described by Marin et al6 in 1994 using a Palmaz stent
(Cordis, Miami Lakes, Fla) mounted on a PTFE graft.
Since then, multiple studies have proven the feasibility of
endovascular PAA repair. The introduction of covered
stents, such as the Viabahn endoprosthesis, has enhanced
our ability to offer a minimally invasive therapy to patients
who are at increased risk for open surgical repair.
With improvement of stent graft technology and endo-
vascular technique, the results of endovascular repair have
improved signiﬁcantly. Primary and secondary patency of
endovascular repair of PAA have been reported as high as
80% and 90% at 1 year and 77% and 87% at 2 years of
follow-up.17,18 Early comparisons between endovascular
and open repair of PAAs using the Viabahn endoprosthesis
have shown similar patency and survival beneﬁts of 83% vs
69% to 86% and 90% vs 87% to 98% up to 2 years.7,17,18,20
Endovascular repair, therefore, has been gaining wide
acceptance. A review of the Centers for Medicare and
Medicaid inpatient claims between 2005 and 2007 identi-
ﬁed an increase in endovascular interventions for PAA from
11.7% to 23.6%.19
The available data on the endovascular management of
acute complications of PAAs is limited to a few case
reports. In one of the earlier series, patients with acute
limb ischemia comprised a small portion of the patients
treated with an endograft.20 Elective operative manage-
ment of PAA is associated with higher bypass graft patency
(94.1% vs 66.7%), as well as a higher limb salvage rate
(97.1% vs 56.3%) than emergency repair. Acutely throm-
bosed PAAs are frequently initially managed with throm-
bolytic therapy, followed by deﬁnitive repair for mild to
moderately threatened limbs (Rutherford class I and
II-a).15 This approach has decreased the role of surgical
thrombectomy because thrombolytic therapy resulted in
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86%).21,22 For severely threatened limbs (Rutherford class
II-b), there is often not enough time to pursue thrombol-
ysis and emergent bypass is required. If there is no patent
distal target vessel for bypass, open thrombectomy of one
or more of the crural vessels is necessary to provide outﬂow
to the foot and a distal bypass target.
Our experience suggests that endovascular repair of
PAA can be successfully accomplished with good short-
term and midterm outcomes, even in patients with acute
presentation. Acute complications of PAA, however, can
be devastating, as supported by the high mortality
(16.6%) in the emergent group in this study.
Several factors may be associated with the relatively
good results obtained in the emergent cases. Because our
institution is a large rural tertiary center, patients are
frequently referred in a timely fashion and resources are
readily available. The aggressive use of thrombolysis has
been demonstrated to improve 1-year patency rates in cases
of acute limb ischemia due to PAA thrombosis.23 The
possibility of rare but severe complications of thrombolysis,
however, should always be discussed with the patient, as we
experienced in one of our deaths, preceded by an intracra-
nial hemorrhage in a 74-year-old man.
Bleeding complications of percutaneous procedures,
especially in patients on thrombolysis, are also increased.
Four of our patients presented with groin hematoma, all
of which occurred in patients with a percutaneous access
and the use of large 10F sheaths. The proﬁle of the Via-
bahn stent graft has recently been reduced. Whether this
will reduce groin complications remains to be seen.
Viabahn stent grafts with heparin bonding were intro-
duced to the U.S. market in September 2007. Heparin
molecules are covalently bonded directly to the Viabahn
surface, and according to the manufacturer, they remain
stable over the life the stent graft. We were unable to show
a difference in patency with and without heparin bonding,
although the number of stents in each group was small.
Whether heparin bonding indeed improves patency rates
or decreases complication rates remains to be seen. There
have been some recent reports of heparin-induced thrombo-
cytopenia related to heparin-bonded expanded PTFE.24
Stent graft complications, in addition to thrombosis,
include endoleaks, stent infolding, and fractures. We
encountered a 9.6% rate of type II endoleaks. However,
all were self-limited and none had aneurysm expansion.
This compares favorably with the ﬁndings by Tielliu
et al,8 who reported type II endoleaks occurring in 10.6%
of their patients, with expansion occurring in 5.3% at 50
months of follow-up. Our ﬁndings and those of Tielliu
et al contrast favorably to those reported by Ravn et al25
with open surgical repair, who reported aneurysm growth
in 8.3% (2 of 24) of their patients after open repair through
a posterior approach. The low incidence of aneurysm
expansion after EVPAR makes predeployment emboliza-
tion of geniculate vessels unnecessary in most patients.
Infolding of the stent graft occurred in one patient,
and others have reported this complication as well.26Oversizing the stent graft by >15% should therefore be
avoided. Stent graft ruptures are rare but warrant contin-
uous late follow-up. The overall high rate of 35.5% for
major adverse events, including death, stent graft throm-
bosis, stent graft revision, conversion, or reoperation for
endoleak or hematoma after EVPAR is worrisome.
Although this series includes our learning curve of the
procedure, there is a need for further improvement in
endovascular technology and adjuvant therapy. On the
basis of our results, the gold standard of PAA repair
remains the open procedure, performed with a saphenous
vein graft, as we reported earlier.
As in any retrospective study of small sample size, our
review and conclusions also have serious limitations.
Although mortality, limb salvage, and patency rates in
emergency repairs were not noted to be signiﬁcantly
different from those in elective repairs, there was a trend
for increased complications, and a type 2 error in our calcu-
lations is very likely. Our follow-up is short, and further
problems with stent grafts affecting data on durability will
most likely be encountered.
CONCLUSIONS
EVPAR is feasible in elective and emergency settings.
Our results support elective EVPAR in anatomically suit-
able patients with increased risk for open repair; however,
major adverse events after EVPAR, more so after emer-
gency repairs, are frequent. Although there was a trend
for increased mortality, limb loss, and decreased primary
patency rate after emergency repair, the difference was
statistically not signiﬁcant. The low number of emergency
procedures may explain that lack of statistical signiﬁcance.
In addition, most of the major adverse events, leading to
death, occlusion, or reoperation, occurred in those who
underwent emergency repair. To justify EVPAR in the
emergency setting, larger number of patients and longer
follow-up is needed. A prospective randomized multicenter
study in this group of patients is clearly warranted.
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